Skip to main content
NewslettersWatchlist

Jazz Pharma Plc(JAZZ-Q)
NASDAQ

Today's Change
Real-Time Last Update Last Sale Cboe BZX Real-Time
Day Low120.07
Day High125.64
Open:121.84
Price movement based on the high, low and last over the given period.
Previous Close
52-Week High/Low
Volume
Average Volume
Price/Earnings (TTM)
Forward Annual Dividend & Yield
Market Capitalization, $M
5-Day Change
Realtime quote and/or trade prices are not sourced from all markets.
Select a category then submit the form to load news
Motley Fool
Billionaire Seth Klarman Sold 64% of Baupost's Stake in Alphabet and Is Piling Into This Historically Cheap and Under-the-Radar Drugmaker
Barchart
S&P 500 and Nasdaq 100 Fall from Record Highs as Chip Stocks Retreat
Barchart
Stocks are Mixed in Midday Trade
Barchart
Chip Stocks Rally to Push the S&P 500 and Nasdaq 100 to New Record Highs
Motley Fool
3 No-Brainer Stocks to Buy With $300 Right Now
Motley Fool
4 Exhilarating Growth Stocks You'll Regret Not Buying in the Wake of the Nasdaq Bear Market Dip
Motley Fool
4 Eye-Catching Growth Stocks You'll Regret Not Buying in the Wake of the Nasdaq Bear Market Dip
Motley Fool
2 Incredible Growth Stocks That Are Screaming Buys for 2024
Motley Fool
4 Remarkable Growth Stocks You'll Regret Not Buying in the Wake of the Nasdaq Bear Market Dip
Motley Fool
3 No-Brainer Stocks to Buy With $500 Right Now
Motley Fool
3 Biotech Stocks That Could Be Millionaire Makers
Motley Fool
3 No-Brainer Stocks to Buy With $200 Right Now
Barchart
Stocks Slump as Middle East Tensions Persist
Barchart
Stocks Fall as Middle East Jitters Spark Risk Aversion in Asset Markets
Barchart
Markets Today: Stocks Fall as Middle East Tensions Ratchet Higher
PR Newswire
Jazz Pharmaceuticals to Present Latest Advancements in Sleep Medicine at World Sleep 2023
PR Newswire
Jazz Pharmaceuticals to Showcase Growing Impact in Solid Tumor Oncology Research at ESMO 2023
Motley Fool
2 Top Biotech Stocks to Buy in October
Motley Fool
5 Genius Safe Stocks to Buy for the 4th Quarter of 2023
Motley Fool
4 Perfect Growth Stocks You'll Regret Not Buying in the Wake of the Nasdaq Bear Market Dip
PR Newswire
Revolutionary Cancer Treatment Advances Promise Brighter Future Amid Federal Funding Uncertainty
PR Newswire
Jazz Pharmaceuticals Receives European Commission Approval for Enrylaze® (a recombinant Erwinia asparaginase or crisantaspase) for the Treatment of Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma

Profile

Jazz Pharmaceuticals is a specialty biopharmaceutical company with a focus in the areas of neuroscience & oncology. It derives the majority of its revenues from its sleep disorder drugs' Xywav & Xyrem. Both drugs are approved for treating cataplexy & excessive daytime sleepiness in narcolepsy patients. Other drugs in the company's neuroscience portfolio include' Sunosi, Epidiolex & Sativex. Epidiolex is approved for treating seizures associated with two rare & severe forms of epilepsy' Lennox-Gastaut syndrome & Dravet syndrome. Sativex is approved in the U.K. & Canada as a treatment for symptom improvement in adult patients with moderate-to-severe spasticity due to multiple sclerosis. Jazz's oncology portfolio includes two drugs' Defitelio for the treatment hepatic veno-occlusive disease with renal or pulmonary dysfunction following hematopoietic stem cell transplantation & Vyxeos for the treatment of adults with two types of acute myeloid leukemia. It received approval for two new drugs' Zepzelca & Rylaze'.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2024.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).

Copyright © 2024 Morningstar. All Rights Reserved. The information contained herein: (1) is proprietary to Morningstar and/or its content providers; (2) may not be copied or distributed; and (3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information. Past performance is no guarantee of future results.